Loading...
•
Dec 31, 2022
Harrow Q4 2022 Earnings Report
Announced fourth quarter and year-end 2022 financial results.
Key Takeaways
Harrow announced its Q4 and year-end results, highlighting a transformational year with the FDA approval of IHEEZO™ and the expansion of their product portfolio.
IHEEZO™ received FDA approval in September 2022.
A permanent J-Code (J2403) and Transitional Pass-Through Reimbursement payment status were issued for IHEEZO™ in 2023.
The company expanded its product portfolio with branded and compounded pharmaceutical products.
Harrow divested its non-ophthalmic-related assets, becoming a pure-play ophthalmic pharmaceutical company.
Forward Guidance
Harrow is excited and prepared for what 2023 and beyond has in store, but the report also contains forward-looking statements that are subject to risks and uncertainties.
Challenges Ahead
- The continued impact of the COVID-19 pandemic and any future health epidemics on financial condition, liquidity and results of operations.
- Ability to make commercially available FDA-approved products and compounded formulations and technologies in a timely manner or at all.
- Market acceptance of the Company’s products and challenges related to the marketing of the Company’s products.
- Risks related to pharmacy operations.
- Ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of products.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...